SOURCE-LINKED STUDY SUMMARY
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Abstract summarizedQuality not appraised
- What was studied
- Randomized trial comparing tirzepatide with placebo for cardiovascular death or worsening heart failure, and patient-reported health status.
- Who / model studied
- 731 people with obesity and heart failure with preserved ejection fraction; median follow-up was 104 weeks, with health-status assessment at 52 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The first primary outcome occurred in 9.9% versus 15.3%. Worsening heart failure occurred in 8.0% versus 14.2%; cardiovascular deaths were 2.2% versus 1.4%. The other primary outcome, health-status score, improved 19.5 versus 12.7 points. Adverse events, mainly digestive, led to stopping treatment in 6.3% versus 1.4%.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2410027